AstraZeneca announced that it has reached an agreement to acquire Actavis-branded respiratory medicines in the United States and Canada for an initial consideration of $600 million.
Thursday 5 February 2015 – Reuters Italy
LONDON, Feb 5 (Reuters) - AstraZeneca said it has reached an agreement to acquire Actavis-branded respiratory medicines in the United States and Canada for an initial consideration of $600 million.
The announcement comes at the same time as the accounts for the fourth quarter, results below expectations.
The group also estimated an 'average single digit' decline in revenues in 2015 (at constant exchange rates). However, core earnings per share are expected to increase in the 'low single digits'.
In detail, fourth quarter revenues fell 2% to $6.68 billion, with core earnings down 38% to 76 cents per share.
Analysts had estimated sales of $6.79 billion and earnings of 82 cents per share for the quarter.
The stock yields 2.6% on the stock exchange.
Related news: Net profit up 18.1% for the Sanofi group
Note:
CEO of AstraZeneca is Pascal Soriot, 55 years old. During the 2013 fiscal year, he received a total compensation of £3,344,000 (Pounds)
CEO of Actavis is Brenton L. Saunders JD., 44 years old. He has been CEO since 1 July 2014
Sanofi's interim CEO is Serge Weinberg, 63 years old. During the 2013 fiscal year, he received a total compensation of €708,040. He has been provisional CEO of Sanofi since October 29, 2014, pending the appointment of the new CEO. He replaced Christopher Viehbacher, fired, which in 2013 received compensation for a total of € 8.648.326.
